Drug Profile

VTX 958

Alternative Names: TYK2 inhibitor-Ventyx Biosciences; VTX-958

Latest Information Update: 06 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ventyx Biosciences
Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Small molecules
Mechanism of Action TYK2 kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Crohn's disease
Research Autoimmune disorders
Discontinued Plaque psoriasis; Psoriatic arthritis

Most Recent Events

04 Mar 2026 Ventyx Biosciences has been acquired by Eli Lilly and Company
07 Nov 2025 VTX 958 is available for licensing as of 07 Nov 2025. www.ventyxbio.com
18 Feb 2025 Efficacy data from a phase II HARMONY trial in Crohn's disease released by Ventyx Biosciences

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com